Researchers at University College London have identified a biological mechanism that helps the human body bring inflammation to an end, a discovery reported in Nature Communications that could lead to new treatments for chronic conditions like arthritis and heart disease. According to University College London scientists, a group of fat-derived molecules known as epoxy-oxylipins act as natural brakes on the immune system by preventing the overproduction of inflammatory white blood cells.
How the Body’s Natural Off Switch Works Against Chronic Inflammation
Inflammation serves as a critical frontline defense mechanism that allows the body to fight infections and repair damaged tissue. However, when this immune response fails to deactivate, it persists and begins damaging healthy tissue, driving major global health threats such as cardiovascular disease, diabetes, and autoimmune disorders. While medical science has long understood how the inflammatory process begins, scientists understood far less about how the body signals that a threat has passed and shifts toward tissue repair, according to University College London researchers.
The newly published study points to epoxy-oxylipins as key signaling molecules in this transition. These fat-derived compounds suppress the accumulation of intermediate monocytes, a specific type of white blood cell that supports short-term healing but fuels chronic inflammation if too many remain active. To observe this biological shutdown in humans, University College London researchers injected healthy volunteers with a tiny amount of UV-killed E. coli bacteria in the forearm. This method produced a temporary, non-infectious inflammatory response characterized by local pain, redness, heat, and swelling.
Clinical Testing of GSK2256294 Reveals Faster Pain Resolution
To test whether boosting epoxy-oxylipins could control immune activity, the research team administered a drug called GSK2256294 to participants at different stages of the trial. The drug blocks soluble epoxide hydrolase, an enzyme that normally breaks down protective epoxy-oxylipins. By inhibiting this enzyme, the drug allows higher levels of these beneficial molecules to remain active in the body. The trial evaluated a prophylactic arm where 24 volunteers (12 treated and 12 untreated) received the drug two hours before inflammation started, and a therapeutic arm where 24 volunteers (12 treated and 12 untreated) received the drug four hours after inflammation began.
Both dosing strategies yielded similar outcomes. According to the study data, blocking soluble epoxide hydrolase increased epoxy-oxylipin levels, helped pain resolve more quickly, and sharply reduced intermediate monocyte counts in both blood and tissue samples. Interestingly, the treatment did not significantly alter outward physical signs such as redness or swelling, indicating that the drug specifically targets deeper immune pathways rather than surface symptoms. Dr. Olivia Bracken, first author from the University College London Department of Ageing, Rheumatology and Regenerative Medicine, stated that the findings reveal a natural pathway limiting harmful immune cell expansion.
Did You Know?
Intermediate monocytes help coordinate short-term immune responses and tissue repair, but when these cells persist, they keep the immune system locked in an active state that drives chronic inflammatory diseases.
Targeting the p38 MAPK Pathway for Safer Treatments
At the molecular level, the research team discovered that a specific epoxy-oxylipin known as 12,13-EpOME suppresses a protein signaling pathway called p38 MAPK. This pathway drives the transformation of monocytes into the intermediate form associated with prolonged inflammatory activity. Scientists confirmed this mechanism through laboratory experiments and by administering a direct p38-blocking drug to human volunteers. Professor Derek Gilroy, corresponding author from the University College London Division of Medicine, noted that this represents the first human-based study mapping epoxy-oxylipin activity during inflammation.
Many conventional treatments for autoimmune and inflammatory conditions rely on broad immune suppression, which leaves patients vulnerable to infections by weakening their overall immune defenses. By contrast, enhancing the body’s natural epoxy-oxylipin pathway offers a strategy to restore immune balance without compromising overall immunity. Because the trial utilized a drug already suitable for human use, the compound could potentially be repurposed to treat flare-ups in chronic inflammatory diseases, an area currently bereft of effective therapies, according to University College London researchers.
Implications for Arthritis and Future Clinical Trials
The findings pave the way for upcoming clinical trials investigating soluble epoxide hydrolase inhibitors in chronic inflammatory conditions like rheumatoid arthritis, an autoimmune disease where the immune system attacks joint linings.
Frequently Asked Questions
What is inflammation?
Inflammation is a natural defense response where the immune system fights infections and repairs damaged tissue. However, chronic or lingering inflammation can damage healthy tissue and contribute to arthritis, heart disease, and diabetes.
What are epoxy-oxylipins?
Epoxy-oxylipins are small, fat-derived molecules naturally produced by the body that act as brakes on the immune system, helping to calm inflammation and reduce the accumulation of harmful immune cells.
How did researchers study inflammation in humans?
University College London researchers administered a tiny injection of UV-killed E. coli bacteria into the forearms of healthy volunteers, triggering a temporary, non-infectious inflammatory response with localized pain, redness, heat, and swelling.
What does the drug GSK2256294 do?
The drug blocks an enzyme called soluble epoxide hydrolase, which normally breaks down epoxy-oxylipins. Blocking this enzyme increases protective epoxy-oxylipin levels, helps resolve pain faster, and reduces inflammatory intermediate monocytes.
What are your thoughts on this discovery? Share your perspective in the comments below, explore our latest medical research articles, or subscribe to our newsletter for updates on immunology and chronic disease treatments.
Keep reading